February 27, 2018
Kissei Pharmaceutical is looking to raise its profile in the area of inflammatory bowel disease (IBD) as it made a full-fledged entry into this market late last year with Rectabul (budesonide), an ulcerative colitis (UC) treatment being copromoted with EA...read more